Study guide

15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias

Key Takeaways Explain This Topic AI

World Health Organization (WHO) and ACOG define anemia in non-pregnant women as hemoglobin <12.0 g/dL (hematocrit <36%); in pregnant women, gestational plasma volume expansion lowers diagnostic thresholds to hemoglobin <11.0 g/dL (hematocrit <33%) in the first and third trimesters, and <10.5 g/dL (hematocrit <32%) in the second trimester.

Iron deficiency anemia (IDA) is the most prevalent cause of microcytic anemia (MCV <80 fL) in women, characterized by serum ferritin <30 ng/mL (the most sensitive and specific diagnostic marker), elevated total iron-binding capacity (TIBC), transferrin saturation <16%–20%, and elevated red cell distribution width (RDW >14.5%).

Thalassemia minor presents with mild microcytosis (MCV <75 fL) disproportionate to mild anemia, a normal or high total RBC count (>5.0 million/mcL), normal RDW, and a Mentzer index (MCV/RBC) <13, confirmed by hemoglobin electrophoresis demonstrating elevated HbA2 (>3.5%) in beta-thalassemia trait.

Macrocytic anemias (MCV >100 fL) are categorized into megaloblastic (impaired DNA synthesis with hypersegmented neutrophils and oval macrocytes) and non-megaloblastic (hypothyroidism, liver disease, reticulocytosis); Vitamin B12 deficiency causes neurological deficits and elevated levels of both methylmalonic acid (MMA) and homocysteine, whereas folate deficiency presents with normal MMA and elevated homocysteine without neurologic compromise.

First-line IDA therapy consists of oral ferrous sulfate (324 mg / 65 mg elemental iron) dosed once daily or every other day with ascorbic acid to prevent hepcidin surges; intravenous iron formulations (iron sucrose, ferric carboxymaltose) are indicated for severe second- or third-trimester IDA, oral intolerance, malabsorption (celiac disease, bariatric surgery), or heavy ongoing uterine bleeding.

Last updated: October 2026

Diagnostic Definitions & Gestational Hemodilution: WHO & ACOG Criteria

Anemia represents a reduction in circulating red blood cell (RBC) mass, hemoglobin (Hb) concentration, or hematocrit (Hct), impairing systemic tissue oxygenation. Diagnostic thresholds vary based on biological sex and gestational status:

  • Patient Population Hemoglobin (Hb) Cutoff Hematocrit (Hct) Cutoff Diagnostic Authority
  • Non-Pregnant Adult Females <12.0 g/dL (120 g/L) <36.0% (0.36) WHO, ACOG, CDC
  • Pregnant Females: First Trimester <11.0 g/dL (110 g/L) <33.0% (0.33) ACOG, CDC, WHO
  • Pregnant Females: Second Trimester <10.5 g/dL (105 g/L) <32.0% (0.32) ACOG, CDC
  • Pregnant Females: Third Trimester <11.0 g/dL (110 g/L) <33.0% (0.33) ACOG, CDC, WHO
  • Postpartum Females <10.0 g/dL (100 g/L) <30.0% (0.30) ACOG, WHO
  • Physiological Hemodilution vs. Pathological Anemia

During normal gestation, maternal plasma volume expands by 45% to 50% , while erythropoietin-stimulated red blood cell mass expands by only 20% to 30% . This disproportionate fluid expansion creates physiological hemodilution ("physiologic anemia of pregnancy"), reaching a hemoglobin nadir at 24 to 28 weeks. Hemoglobin concentrations falling below 10.5 g/dL in the second trimester or below 11.0 g/dL in the first or third trimesters represent true pathological anemia requiring clinical intervention to avoid maternal exhaustion, cardiac strain, preterm delivery, and low birth weight.

Microcytic Anemias: Iron Deficiency, Thalassemia & Chronic Disease

Mean Corpuscular Volume (MCV) categorizes anemias into microcytic (<80 fL), normocytic (80–100 fL), and macrocytic (>100 fL). Microcytic anemias result from impaired hemoglobin synthesis:

1. Iron Deficiency Anemia (IDA)

Iron deficiency is the leading cause of anemia worldwide, accounting for >50% of cases in women. Etiologies in females include heavy menstrual bleeding (AUB/menorrhagia), high gestational demands (~1,000 mg total pregnancy iron requirement: 300 mg fetus/placenta, 500 mg RBC expansion, 200 mg excretion), nutritional insufficiency, and malabsorption (celiac disease, H. pylori , bariatric bypass).

Diagnostic Profile:

Serum Ferritin: The single most sensitive and specific marker; ferritin <30 ng/mL confirms iron deficiency (<15 ng/mL absolute exhaustion; <30–45 ng/mL in pregnancy).

Total Iron-Binding Capacity (TIBC): Elevated (>400 mcg/dL) due to compensatory hepatic transferrin synthesis.

Transferrin Saturation (TSAT): Depressed (<16%–20%).

Red Cell Distribution Width (RDW): Elevated (>14.5%), reflecting anisocytosis.

Blood Smear: Microcytic, hypochromic RBCs with central pallor, anisopoikilocytosis, and pencil cells.

2. Thalassemia Minor / Trait (Alpha or Beta)

Inherited quantitative globin chain deficiencies characterized by mild microcytic anemia (Hb 10.0–11.5 g/dL) with strikingly low MCV (<75 fL) disproportionate to the mild anemia, accompanied by a normal or high total RBC count (>5.0 million/mcL) and normal RDW (<14%).

Mentzer Index (MCV / RBC count): An index <13 strongly indicates thalassemia trait, whereas an index >13 suggests iron deficiency anemia.

Hemoglobin Electrophoresis: Confirms beta-thalassemia trait via elevated HbA2 >3.5% (normal 1.5%–3.5%) and variable HbF (1%–5%). Alpha-thalassemia trait exhibits normal adult electrophoresis, requiring alpha-globin gene DNA deletion testing.

3. Anemia of Chronic Disease / Chronic Inflammation (ACD)

Driven by inflammatory cytokines (IL-6, TNF-alpha) stimulating hepatic synthesis of hepcidin , which degrades ferroportin channels, trapping iron within macrophages and enterocytes. Laboratory profile: normal or elevated ferritin (>100 ng/mL), low TIBC (<250 mcg/dL), low serum iron, and low-to-normal TSAT.

  • Laboratory Parameter Iron Deficiency Anemia (IDA) Thalassemia Minor / Trait Anemia of Chronic Disease (ACD)
  • MCV Low (<80 fL; proportional) Markedly Low (<75 fL; disproportionate) Normal to mildly low (75–85 fL)
  • Serum Ferritin Low (<30 ng/mL) Normal to elevated (50–300 ng/mL) Normal to Elevated (>100 ng/mL)
  • TIBC Elevated (>400 mcg/dL) Normal (250–400 mcg/dL) Low (<250 mcg/dL)
  • TSAT Low (<16%–20%) Normal to elevated (>20%) Low-to-normal (15%–25%)
  • RDW Elevated (>14.5%) Normal (<14.0%) Normal to mildly elevated
  • Mentzer Index >13 <13 Variable (>13)
  • Normocytic Anemias & Reticulocyte Dynamics

Normocytic anemias (MCV 80–100 fL) are categorized by the reticulocyte production index (RPI) :

Hyperproliferative (RPI >2 or Reticulocytes >2%): Indicates accelerated destruction or loss. Hallmark of hemolytic anemias : elevated indirect bilirubin, elevated lactate dehydrogenase (LDH), suppressed serum haptoglobin (haptoglobin binds free intravascular hemoglobin), and positive Coombs / Direct Antiglobulin Test (DAT) in autoimmune hemolysis.

Hypoproliferative (RPI <2 or Reticulocytes <2%): Indicates impaired erythrocyte production. Common etiologies include chronic kidney disease (CKD) with deficient peritubular erythropoietin secretion, early nutritional deficiency, or bone marrow infiltration.

Macrocytic Anemias: Megaloblastic vs. Non-Megaloblastic Differentiation

Macrocytic anemia is defined by an MCV >100 fL, divided by peripheral blood smear morphology into megaloblastic and non-megaloblastic forms:

1. Megaloblastic Anemia (Impaired DNA Synthesis)

Defective purine and thymidine synthesis delays nuclear replication relative to cytoplasmic RNA synthesis (nuclear-cytoplasmic dyssynchrony). Smear demonstrates macro-ovalocytes and hypersegmented neutrophils (≥1 neutrophil with ≥6 lobes, or ≥5% with ≥5 lobes).

Parameter Vitamin B12 (Cobalamin) Deficiency Folate (Vitamin B9) Deficiency

Primary Causes Pernicious anemia (anti-intrinsic factor antibodies); terminal ileal resection/Crohn disease; strict vegan diet; bariatric surgery; long-term metformin (>3–4 years) or PPI use. Dietary deficiency (lack of green leafy vegetables); alcohol use disorder; antifolate drugs ( methotrexate , trimethoprim, phenytoin); malabsorption; pregnancy.

Neurological Symptoms PRESENT: Subacute combined degeneration of the spinal cord (paresthesias, sensory ataxia, loss of vibratory/position sense, spasticity, dementia). ABSENT: No neurological deficits. (Gestational deficiency causes fetal neural tube defects).

  • Methylmalonic Acid (MMA) ELEVATED (Cobalamin required for methylmalonyl-CoA mutase). NORMAL
  • Homocysteine ELEVATED ELEVATED

Important

Never treat macrocytic anemia with high-dose folic acid alone without excluding Vitamin B12 deficiency. Supplemental folate can correct hematologic abnormalities while allowing irreversible subacute combined degeneration of the spinal cord to progress silently.

2. Non-Megaloblastic Macrocytic Anemia (Normal DNA Synthesis)

Normal DNA synthesis featuring round macrocytes without hypersegmented neutrophils. Etiologies include alcohol use disorder, hepatic cirrhosis, primary hypothyroidism, and marked reticulocytosis.

  • Evidence-Based Iron Repletion: Oral Dosing & Intravenous Indications
  • Oral Iron Dosing Dynamics

Alternate-Day Dosing: A medicinal iron dose triggers an acute rise in hepatic hepcidin that persists for 24 to 48 hours , blocking subsequent intestinal ferroportin channels. Dosing ferrous sulfate (324 mg / 65 mg elemental iron) once daily or every other day avoids hepcidin spikes, increases fractional iron absorption by >30%, and dramatically reduces gastrointestinal adverse effects (nausea, constipation, dark stools).

Administration Rules: Take on an empty stomach with water or vitamin C (ascorbic acid 250–500 mg) to enhance absorption. Avoid concurrent calcium, antacids, dairy, tea, or coffee.

Response: Reticulocytosis peaks at 7 to 10 days; hemoglobin rises by 1.0 to 2.0 g/dL every 2 to 4 weeks. Continue oral therapy for 3 to 6 months after hemoglobin normalizes to replenish tissue ferritin (>50 ng/mL).

Intravenous Iron Formulations

Modern IV formulations (iron sucrose, ferric carboxymaltose) bypass intestinal absorption directly into transferrin. Key clinical indications in women's health:

Severe iron deficiency anemia in the late second or third trimester (Hb <9.0–10.0 g/dL after 28 weeks), where rapid repletion is mandatory prior to delivery.

Oral iron intolerance causing intractable gastrointestinal side effects.

Gastrointestinal malabsorption: active celiac disease, inflammatory bowel disease, post-Roux-en-Y gastric bypass.

Intractable heavy menstrual bleeding exceeding oral absorption capacity.